

## **Weerawadee Chandranipapongse, M.D.**

Department of Pharmacology, Faculty of Medicine Siriraj Hospital Tel: (662) 419-7565  
2 Wanglang Road, Siriraj Fax: (662)411-5026  
Bangkok, Thailand 10700 Mobile phone: (6681) 625-9011  
Date of birth: May 20, 1978 Email: weerawadee.cha@mahidol.ac.th

---

### **Medical Education**

#### **Faculty of Medicine, University of Toronto, Toronto, Canada**

Certification of Clinical Fellowship in Clinical Pharmacology and Toxicology, July 1, 2011-June 30, 2013

#### **Faculty of Medicine Siriraj Hospital, Mahidol University under The Medical Council of Thailand, Bangkok, Thailand**

Diploma in Pediatric specialty, July 2008

#### **Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand**

Graduate Diploma Programme in Clinical Science in Pediatrics, March 2006

#### **Chainat Provincial Hospital, Chainat, Thailand**

Completed a General Medical Internship, 2002-2003

#### **Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand**

Doctor of Medicine, March 2002

### **Work Experience**

#### **Siriraj Hospital Department of Pharmacology, Mahidol University, Bangkok, Thailand**

Lecturer, 2008-present

Internship, 2003-2005

#### **Siriraj Hospital Department of Pediatrics, Mahidol University, Bangkok, Thailand**

Pediatrician, 2008-present

#### **Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada**

Clinical fellow, July 1, 2011-June 30, 2013

### **Credentials**

Certification in Good Clinical Research Practice: GCP Training, March 13<sup>th</sup>-14<sup>th</sup>, 2014

Certification in Ethical Issues in Clinical Trials, February 25<sup>th</sup>, 2014

Certification of Clinical Fellowship in Clinical Pharmacology and Toxicology, University of Toronto, June, 2013

Board Certification in Pediatrics from The Medical Council of Thailand and The Royal College of Pediatricians of Thailand, July, 2008

General license to practice medicine in Thailand, April, 2002

### **Presentations**

Tanoshima R, **Chandranipapongse W**, Colantonio D, Stefan C, Nulman I. Acute olanzapine overdose in a Toddler: a case report with pharmacological insights. Poster presentation at the Modern Therapeutics 2012: Advances in physiology, pharmacology and pharmaceutical sciences, June 12-15, 2012.

Chiochanwisawakit P, Nilganuwong S, Srinonprasert S, Boonprasert R, **Chandranipapongse W**, Chatsiricharoenkul S, et al. Prevalence and risk factors of chloroquine maculopathy; Do plasma chloroquine and desethylchloroquine concentration

associate with chloroquine maculopathy. Poster presentation at the European League Against Rheumatism 2012, June 6-9, 2012.

**Chandranipapongse W**, Ito S. Quality of reporting in studies of drug excretion into human milk. Poster presentation at the 2012 American Society for Clinical Pharmacology and Therapeutics, March 14-27, 2012.

**Chandranipapongse W**, Ruangnapa T, Pongnarin P, Sathirakul K, Kongpatanakul S. Bioequivalence Study of Two Formulations of 35 mg Trimetazidine Modified Release Tablets in Thai Healthy Volunteers. Poster presentation at the 16<sup>th</sup> World Congress on Basic and Clinical Pharmacology, July 17-23, 2010.

**Chandranipapongse W**, Chatsiricharoenkul S, Pongnarin P, Sathirakul K, Kongpatanakul S. In Vivo Bioequivalence Study of Two Formulations of 30 mg Pioglitazone Tablets in Thai Healthy Volunteers. Poster presentation at the Joint Conference in Medical Sciences 2009, June 22, 2009.

**Chandranipapongse W**, Chomchai C, Dansirikul C. The preliminary project: population pharmacokinetics study of theophylline in Thai premature infants. Oral presentation at the 65<sup>th</sup> Congress of The Royal College of Pediatricians of Thailand and Pediatric society of Thailand, April 24, 2007.

**Chandranipapongse W**, Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S, Palo T. The effects of ascorbic acid on COX and NOS isoform expression in EGF-treated HUVEC. Oral presentation at Siriraj annual meeting of the year 2004, March 2004

## **Publications**

1. Sri-in J, Prakobkijcharoen J, Thanakosai W, Chatsiricharoenkul S, **Chandranipapongse W**. Liquid chromatography tandem mass spectrometry method for simultaneous determination of losartan and its active metabolite in human plasma. *Pharm Sci Asia*. 2018; 45(4):252-62.
2. Sirikarin T, Palo T, Chotewuttakorn S, **Chandranipapongse W**, Limsuvan S, Akarasereenont P. The effects of *Andrographis paniculata* on platelet activity in healthy Thai volunteers, *Evid Based Complement Alternat Med*, vol. 2018, Article ID 2458281, 9 pages, 2018. <https://doi.org/10.1155/2018/2458281>.
3. Pongnarin P, Thanakosai W, Kingkhangphloo P, **Chandranipapongse W**, Kongpatanakul S, Chatsiricharoenkul S. Development and validation of liquid chromatography - tandem mass spectrometry method for determination of amlodipine in human plasma and its application. *Pharm Sci Asia* 2017; 44 (4):217-226.
4. **Chandranipapongse W**, Palo T, Chotewuttakorn S, Tripatara P, Booranasubkajorn S, Laohapand T, et al. Study the effect of an antipyretic Drug, Thai herbal Ha-rak formula on platelet aggregation in healthy Thai volunteers: a randomized, placebo - controlled trial. *Siriraj Med J* 2017;69: 283-289.
5. Burnett HF, Tanoshima R, **Chandranipapongse W**, Madadi P, Ito S, Ungar WJ. Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents. *Pharmacogenomics J*. 2014;14(6):493-502.
6. Tanoshima R, **Chandranipapongse W**, Colantonio D, Stefan C, Nulman I. Acute olanzapine overdose in a toddler: a case report. *Ther Drug Monit* 2013;35(5):557-9.

7. **Chandranipapongse W**, Koren G. Preconception counseling for preventable risks. *Can Fam Physician* 2013;59(7):737-9.
8. Chiowchanwisawakit P, Nilganuwong S, Srinonprasert V, Boonprasert R, **Chandranipapongse W**, Chatsiricharoenkul S, et al. Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. *Int J Rheum Dis* 2013;16(1):47-55.
9. Boonprasert R, Sri-in J, Pongnarin P, Chatsiricharoenkul S, **Chandranipapongse W**. Development of the liquid chromatography tandem mass spectrometry method for determination of chloroquine and desethylchloroquine in human plasma. *Siriraj Med J* 2012;64:47-51.
10. **Chandranipapongse W**, Ito S. Quality of reporting in studies of drug excretion into human milk (Abstract). *Clin Pharmacol Ther* 2012;91(Suppl 1):S88.
11. **Chandranipapongse W**, Chatsiricharoenkul S, Ruangnapa T, Ngokpol S, Sathirakul K, Pongnarin P, et al. Bioequivalence study of two formulations of 35mg trimetazidine modified release tablets in healthy Thai volunteers under fasting and fed conditions. *J Bioequiv Availab* 2011;3(3):52-5.
12. **Chandranipapongse W**, Chatsiricharoenkul S, Pongnarin P, Sathirakul K, Kongpatanakul S. Bioequivalence Study of Two Formulations of 30 mg Pioglitazone Tablets in Thai Healthy Volunteers. *Chiang Mai Med J* 2010;49(1):1-10.

## **Affiliations**

Member of the Thai Medical Council,  
Member of the Royal College of Pediatricians of Thailand